First tolvaptan filing for ADPKD accepted, in US
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review the first approval filing worldwide for Otsuka Pharmaceutical's tolvaptan for the additional orphan indication of autosomal dominant polycystic kidney disease (ADPKD).